Plain-English translation of NCT05570422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called that is injected directly into cervical tumors. The medication is given alongside standard radiation therapy and chemotherapy to see if it is safe and whether it helps shrink tumors in women with locally advanced cervical cancer. The study has two parts: first, researchers will test different doses of the medication in a small group of patients, and then they will compare it to standard treatment alone in a larger group.
Cervical cancer that has spread locally is serious and difficult to treat. Doctors want to find ways to make radiation therapy more effective by combining it with this new medication, which may help the body's immune system attack cancer cells more powerfully.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the standard cervical cancer treatment (weekly chemotherapy pills combined with daily radiation therapy over 5 weeks, followed by specialized internal radiation). If you are in the group receiving the new medication, you will also receive injections of directly into your tumor, starting in the second week of treatment. The study involves regular clinic visits over about 8 weeks to receive treatment, have imaging scans, and let doctors monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
India
Thailand
United Kingdom